PDE4A and psoriasis: As PDE4 inhibitors have been recently approved for clinical use in COPD (Rabe, 2011; Wedzicha et al., 2016) and psoriasis (Rich et al., 2016), our present results encourage further research to validate the use of these drugs in patients with CF.